Stryker Corporation (NYSE:SYK) Shares Purchased by Calamos Advisors LLC

Calamos Advisors LLC grew its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 9.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 93,786 shares of the medical technology company's stock after buying an additional 8,264 shares during the period. Calamos Advisors LLC's holdings in Stryker were worth $34,912,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in SYK. Norges Bank purchased a new stake in shares of Stryker during the 4th quarter valued at $1,710,744,000. GAMMA Investing LLC grew its stake in shares of Stryker by 43,226.8% during the 1st quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company's stock valued at $772,390,000 after buying an additional 2,070,133 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Stryker during the 4th quarter valued at $353,394,000. FMR LLC grew its stake in shares of Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after buying an additional 727,850 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Stryker during the 4th quarter valued at $154,140,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on SYK. Wall Street Zen cut shares of Stryker from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Truist Financial upped their price target on shares of Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research report on Monday, May 5th. BTIG Research set a $403.00 price target on shares of Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Finally, Evercore ISI decreased their price target on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and an average price target of $427.30.

Stryker Stock Up 0.0%

NYSE:SYK traded up $0.19 on Friday, reaching $392.00. The stock had a trading volume of 536,295 shares, compared to its average volume of 1,346,875. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69. The company has a 50-day moving average of $382.39 and a 200 day moving average of $375.99. The stock has a market cap of $149.62 billion, a P/E ratio of 52.97, a price-to-earnings-growth ratio of 2.98 and a beta of 0.91. Stryker Corporation has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.50 EPS. On average, research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Insider Activity

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.90% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.